Association between the expression pattern of p16, pRb and p53 and the response to intravesical bacillus Calmette–Guerin therapy in patients with urothelial carcinoma in situ of the urinary bladder
Authors:
- 26 July 2011
- journal article
- research article
- Published by Wiley in Pathology International
- Vol. 61 (8) , 456-460
Abstract
There is limited data regarding the association between the expression of cell cycle‐regulating molecules and the response of patients with urothelial carcinoma in situ (CIS) to bacillus Calmette–Guerin (BCG) therapy. To examine the relationship between p16, pRb and p53 expression in bladder CIS and patient response to initial BCG therapy, we performed immunohistochemical studies for 27 patients with bladder CIS. Overexpression of p16, pRb, and p53 was observed in 37%, 41%, and 48% of patients, respectively. Initial BCG therapy was effective in 21 patients (78%). Coexistence of papillary urothelial carcinoma, depth (pTa or pT1) and grade of coexisting papillary carcinoma did not affect the response to BCG therapy. pRb overexpression had a significant relationship to poor response to BCG therapy (P= 0.027). The results of this study indicate that overexpression of pRb in bladder CIS predicts poor response of intravesical BCG instillation and status of p16 and p53 may not be predictive of initial BCG failure.Keywords
This publication has 14 references indexed in Scilit:
- Molecular pathways of urothelial development and bladder tumorigenesisUrologic Oncology: Seminars and Original Investigations, 2010
- Retinoblastoma protein expression predicts response to bacillus Calmette-Guérin immunotherapy in patients with T1G3 bladder cancerUrologic Oncology: Seminars and Original Investigations, 2010
- p16INK4a Expression Analysis as an Ancillary Tool for Cytologic Diagnosis of Urothelial CarcinomaAmerican Journal of Clinical Pathology, 2009
- p16ink4 immunoreactivity is a reliable marker for urothelial carcinoma in situHuman Pathology, 2008
- Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvementBiomedicine & Pharmacotherapy, 2007
- Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon‐alphaCancer, 2007
- Nucleo-cytoplasmic communication in apoptotic response to genotoxic and inflammatory stressCell Research, 2005
- Identification of Chromosome 9 Alterations and p53 Accumulation in Isolated Carcinoma in Situ of the Urinary Bladder versus Carcinoma in Situ Associated with CarcinomaThe American Journal of Pathology, 2002
- Discriminatory Immunohistochemical Staining of Urothelial Carcinoma in Situ and Non-neoplastic UrotheliumAmerican Journal of Surgical Pathology, 2001
- THE LIMITS OF BACILLUS CALMETTE-GUERIN FOR CARCINOMA IN SITU OF THE BLADDERJournal of Urology, 2001